ArticleOncogene2005
Inhibiting angiogenesis and tumorigenesis by a synthetic molecule that blocks binding of both VEGF and PDGF to their receptors.
Article in Oncogene, 2005. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 28 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
28 citing papers in PubMed, 108 citations in OpenAlex.
- Calix[4]API-s: fully functionalized calix[4]arene-based facial active pharmaceutical ingredients.Molecular diversity · 2021Review
- Nanoparticle-Mediated Combination Therapy: Two-in-One Approach for Cancer.International journal of molecular sciences · 2018Review
- Supramolecular Chemistry Targeting Proteins.Journal of the American Chemical Society · 2017Article
- Article
- Molecular underpinnings of corneal angiogenesis: advances over the past decade.International journal of ophthalmology · 2016Review
- Mitochondrial UQCRB regulates VEGFR2 signaling in endothelial cells.Journal of molecular medicine (Berlin, Germany) · 2013Article
- In vivo characterization of 68Ga-NOTA-VEGF 121 for the imaging of VEGF receptor expression in U87MG tumor xenograft models.European journal of nuclear medicine and molecular imaging · 2013Article
- Therapeutic development in targeting protein-protein interactions with synthetic topological mimetics.Current opinion in pharmacology · 2012Review
- Glioblastoma-derived tumor cells induce vasculogenic mimicry through Flk-1 protein activation.The Journal of biological chemistry · 2012Article
- Novel interactions between NFATc1 (Nuclear Factor of Activated T cells c1) and STAT-3 (Signal Transducer and Activator of Transcription-3) mediate G protein-coupled receptor agonist, thrombin-induced biphasic expression of cyclin D1, with first phase influencing cell migration and second phase directing cell proliferation.The Journal of biological chemistry · 2012Article
- Blocking HIV-1 entry by a gp120 surface binding inhibitor.Bioorganic & medicinal chemistry letters · 2012Article
- PDGF mediates TGFβ-induced migration during development of the spinous process.Developmental biology · 2012Article
- Primary xenografts of human prostate tissue as a model to study angiogenesis induced by reactive stroma.PloS one · 2012Article
- Significantly high expression of platelet-derived growth factor (PDGF) in benign nodules of the thyroid: relevance in the development of goitre recurrence?Langenbeck's archives of surgery · 2011Article
- PET imaging of early response to the tyrosine kinase inhibitor ZD4190.European journal of nuclear medicine and molecular imaging · 2011Article
- Vascular endothelial growth factor as an anti-angiogenic target for cancer therapy.Current drug targets · 2010Review
- Inorganic nanomaterials for tumor angiogenesis imaging.European journal of nuclear medicine and molecular imaging · 2010Review
- Novel aspects of corneal angiogenic and lymphangiogenic privilege.Progress in retinal and eye research · 2010Review
- Discovery of a synthetic dual inhibitor of HIV and HCV infection based on a tetrabutoxy-calix[4]arene scaffold.Bioorganic & medicinal chemistry letters · 2010Article
- A combinatorial approach for the design of complementarity-determining region-derived peptidomimetics with in vitro anti-tumoral activity.The Journal of biological chemistry · 2009Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors at 3 institutions in 1 country.
Funding
Abstract
Angiogenesis depends on vascular endothelial growth factor (VEGF) for initiation and platelet-derived growth factor (PDGF) for maintenance of blood vessels. We have designed a targeted library of compounds from which we identified a novel molecule, GFB-204, that binds PDGF and VEGF, blocks binding of PDGF and VEGF to their receptors (200-500 nM) and subsequently inhibits PDGFR and Flk-1 tyrosine phosphorylation and stimulation of the protein kinases Erk1, Erk2 and Akt and the signal transducer and activator of transcription STAT3. GFB-204 is selective for PDGF and VEGF and does not inhibit EGF, IGF-1 and FGF stimulation of Erk1/2, Akt and STAT3. GFB-204 inhibits endothelial cell migration and capillary network formation in vitro. Finally, treatment of mice with GFB-204 suppresses human tumor growth and angiogenesis. Thus, inhibition of VEGF and PDGF receptor binding with a synthetic molecule results in potent inhibition of angiogenesis and tumorigenesis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.